logo
Cheniere Signs Long-Term Integrated Production Marketing Agreement with Canadian Natural Resources Limited

Cheniere Signs Long-Term Integrated Production Marketing Agreement with Canadian Natural Resources Limited

Business Wire6 days ago

HOUSTON--(BUSINESS WIRE)--Cheniere Energy, Inc. ('Cheniere') (NYSE: LNG) announced today that its subsidiary, Cheniere Marketing, LLC ('Cheniere Marketing'), has entered into a long-term Integrated Production Marketing ('IPM') gas supply agreement with Canadian Natural Resources Limited.
Under the IPM agreement, a subsidiary of Canadian Natural Resources Limited has agreed to sell 140,000 MMBtu per day of natural gas to Cheniere Marketing for a term of 15 years, which is expected to commence in 2030. Canadian Natural Resources Limited is acting as guarantor of the IPM agreement. The liquefied natural gas ('LNG') associated with this gas supply, approximately 0.85 million tonnes per annum ('mtpa'), will be marketed by Cheniere Marketing. Cheniere Marketing will pay an LNG-linked price for the natural gas, based on the Platts Japan Korea Marker (JKM), after deductions for fixed LNG shipping costs and a fixed liquefaction fee. The IPM agreement is subject to Cheniere making a positive Final Investment Decision with respect to the Sabine Pass Liquefaction Expansion Project ('SPL Expansion Project').
The SPL Expansion Project is being developed with an expected total production capacity of up to approximately 20 mtpa of LNG, inclusive of estimated debottlenecking opportunities.
About Cheniere
Cheniere Energy, Inc. is the leading producer and exporter of LNG in the United States, reliably providing a clean, secure, and affordable solution to the growing global need for natural gas. Cheniere is a full-service LNG provider, with capabilities that include gas procurement and transportation, liquefaction, vessel chartering, and LNG delivery. Cheniere has one of the largest liquefaction platforms in the world, consisting of the Sabine Pass and Corpus Christi liquefaction facilities on the U.S. Gulf Coast, with total production capacity of over 46 mtpa of LNG in operation and an additional 8+ mtpa of expected production capacity under construction. Cheniere is also pursuing liquefaction expansion opportunities and other projects along the LNG value chain. Cheniere is headquartered in Houston, Texas, and has additional offices in London, Singapore, Beijing, Tokyo, Dubai and Washington, D.C.
For additional information, please refer to the Cheniere website at www.cheniere.com and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission.
Forward-Looking Statements
This press release contains certain statements that may include 'forward-looking statements' within the meanings of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical or present facts or conditions, included herein are 'forward-looking statements.' Included among 'forward-looking statements' are, among other things, (i) statements regarding Cheniere's financial and operational guidance, business strategy, plans and objectives, including the development, construction and operation of liquefaction facilities, (ii) statements regarding regulatory authorization and approval expectations, (iii) statements expressing beliefs and expectations regarding the development of Cheniere's LNG terminal and pipeline businesses, including liquefaction facilities, (iv) statements regarding the business operations and prospects of third-parties, (v) statements regarding potential financing arrangements, (vi) statements regarding future discussions and entry into contracts, (vii) statements relating to Cheniere's capital deployment, including intent, ability, extent, and timing of capital expenditures, debt repayment, dividends, share repurchases and execution on the capital allocation plan, and (viii) statements relating to our goals, commitments and strategies in relation to environmental matters. Although Cheniere believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Cheniere's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in Cheniere's periodic reports that are filed with and available from the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Other than as required under the securities laws, Cheniere does not assume a duty to update these forward-looking statements.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dollar General Stock Skyrockets Nearly 14%--But Is This Just the Calm Before a Long Decline?
Dollar General Stock Skyrockets Nearly 14%--But Is This Just the Calm Before a Long Decline?

Yahoo

time19 minutes ago

  • Yahoo

Dollar General Stock Skyrockets Nearly 14%--But Is This Just the Calm Before a Long Decline?

Dollar General (NYSE:DG) shares surged nearly 14% at 12.11pm after the company beat Wall Street's Q1 expectations, reporting adjusted earnings of $1.78 per share on $10.4 billion in revenue. Same-store sales rose 2.4%, driven by higher average basket sizes despite softer foot traffic. CEO Todd Vasos noted strong market-share gains in core categories like food and household essentialsplus an encouraging uptick in spending from middle- and high-income consumers. Citi's Paul Lejuez, who upgraded the stock in April, said the quarter was solid enough to support the rally, even with tariff uncertainties still on the radar. Warning! GuruFocus has detected 7 Warning Sign with DG. That near-term boost, however, doesn't erase a broader concern: growth has hit a wall. A look at the last 12 quarters shows revenue stuck between $9 and $10 billion, with net margins hovering in a tight 3.5% to 5% range. Net income and EBITDA have barely budged. Longer-term data suggests Dollar General's strongest growth phase happened years agowell before COVID. While the business rebounded post-pandemic, it hasn't regained that earlier acceleration. Since 2023, results have been flat, pointing to a possible saturation of the current model. In the short term, DG could continue to benefit as a defensive play in a shaky macro environment. But the charts are starting to whisper a tougher truth: this might be as good as it gets without a major shift in strategy. Investors chasing Tuesday's spike may want to pause and ask whether they're buying momentumor just buying time. This article first appeared on GuruFocus. Sign in to access your portfolio

Archer Aviation Gains on First Piloted Runway Flight
Archer Aviation Gains on First Piloted Runway Flight

Yahoo

time19 minutes ago

  • Yahoo

Archer Aviation Gains on First Piloted Runway Flight

Archer Aviation (NYSE:ACHR) shares rose 2.57% after its Midnight eVTOL aircraft completed its first piloted conventional takeoff and landing (CTOL), marking a key step toward commercialization. CTOL flights require rugged landing gear and precise control systemscapabilities that Midnight demonstrated under a clear California sky by accelerating down a runway and lifting off wheels first. Warning! GuruFocus has detected 2 Warning Signs with JOBY. CEO Adam Goldstein said this dual VTOL/CTOL design integrates into a wide range of operational scenarios while providing enhanced safety. Government regulators and defense partners have flagged CTOL as critical for real?world operations, boosting confidence in Midnights design choices as Archer readies production in its new Georgia factory with Stellantis help. While Archer promised 2025 aircraft deliveries, none have occurred yet, and the entire eVTOL sector faces certification hurdles. The CTOL milestone doesnt accelerate the delivery timeline, but it validates technical progress at a time when peers like Joby (NYSE:JOBY) and Vertical Aerospace (EVTL) confront delays. Archer continues to burn cash and must translate milestones into revenue and certification. Investors should care because CTOL success lends critical credibility to Archers promise of an aircraft that can operate from both runways and vertiports, narrowing the gap between hype and reality and keeping Archer in the lead as competition intensifies. It's important to note from the chart above that the stock has surged almost 47% with a 115% CAGR, showing incredible investor confidence. The stock is consolidating near the $9.90 mark at this point. Hence, despite some volatility, the overall momentum remains healthy with support forming above previous lows. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Hims Stock Surges 180%--Now It's Betting Big on Europe's $100B Weight-Loss Market
Hims Stock Surges 180%--Now It's Betting Big on Europe's $100B Weight-Loss Market

Yahoo

time19 minutes ago

  • Yahoo

Hims Stock Surges 180%--Now It's Betting Big on Europe's $100B Weight-Loss Market

Hims & Hers Health (NYSE:HIMS) is doubling down on the global obesity drug boom. The U.S.-based telehealth company just snapped up European rival Zava in a cash deal, opening the door to 1.3 million new patients across the UK, Ireland, Germany, and France. CEO Andrew Dudum called obesity a huge opportunity and believes the path forward lies in personalized carenot just mass prescriptions. With demand already running hot for weight-loss treatments not covered by public healthcare, this acquisition could be Hims' ticket to scale its model far beyond U.S. borders. Warning! GuruFocus has detected 3 Warning Sign with HIMS. In the U.S., Hims built momentum by offering compounded versions of GLP-1 drugs like Wegovy and Zepbound during supply shortagesreplicas that mimicked the active ingredients but were tailored to individual needs. Even now, as shortages ease and compounding restrictions tighten, Hims hasn't exited the scene. Instead, it's pivoting toward more niche personalizations: lower doses, unique formulations, and side-effect-reducing combinations. That same playbook could be viable in the UK and Europe, where local rules still allow "specials"bespoke medications for patients with unique clinical needs. And here's the bigger picture: Hims isn't trying to replace branded drugsit's becoming the neutral platform that offers both. The company recently inked a deal with Novo Nordisk to sell Wegovy directly and expects more collaborations. Think of it like Switzerland: impartial, adaptive, and quietly positioning itself at the center of a lucrative market shift. With shares already up nearly 180% over the past year, investors could be looking at a business that's just getting startedespecially as Europe becomes its next frontier. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store